



PATENT

Case Docket No. STERN1.001APC

Date: November 1, 2002

Page 1

In re application of : Lubbert, Hermann
App. No. : 09/830,703
Filed : April 26, 2001
For : TRANSGENIC ANIMAL MODEL
FOR NEURODEGENERATIVE
DISEASES
Examiner : Qian, C. X.
Art Unit : 1636

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. 2327, Arlington, VA
) 22202, on

November 1, 2002

(Date)

Mark R. Benedict
Mark R. Benedict, Reg. No. 44,531

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 2327
Arlington, VA 22202

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is a *Response to Restriction Requirement and Amendment* in the above-identified application.

(X) An extension of time to respond for three months is hereby requested.

Time Extension Fee:

(X) three months (\$460 small entity)

The fee has been calculated as shown below:


CLAIMS AS FILED						
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims	24	—	24	= 0	\$9	= \$0
Independent Claims	2	—	3	= 0	\$42	= \$0
If application has been amended to contain multiple dependent claim(s), then add					\$140	= \$0
Time Extension Fee						\$460
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$460

11/07/2002 MBIZUNES 00000011 09830703

01 FC:2253

460.00 0P

- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.
- (X) Return prepaid postcard.
- (X) A check in the amount of \$460 is enclosed.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.



Mark R. Benedict
Registration No. 44,531
Attorney of Record
Customer No. 20,995
(949) 760-0404

STERN1.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lubbert, Hermann
Appl. No. : 09/830,703
Filed : April 26, 2001
For : TRANSGENIC ANIMAL
MODEL FOR
NEURODEGENERATIVE
DISEASES
Examiner : Qian, Celine X.

Group Art Unit: 1636

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT
AND
AMENDMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

This is in response to Restriction Requirement set forth in the Office Action, mailed July 2, 2002.

IN THE CLAIMS:

Please amend Claims 8 and 14 as follows:

8. **(Twice amended)** A transgenic non-human mammal comprising an isolated or purified polynucleotide encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease.

14. **(Twice amended)** A method of producing a transgenic animal, comprising:
constructing a vector that carries an isolated or purified polynucleotide encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease;
introducing said vector into embryonic stem cells;

injecting said embryonic stem cells into blastocysts; and
placing said blastocysts into a pseudopregnant female animal.

REMARKS

Independent Inventions Restriction

In response to the Restriction Requirement, Applicant elects with traverse, Group III (Claims 8, 14, 15, 22, and 29). In addition, Applicant would like to request rejoiner of claims from groups IV and V (Claims 17, 18, 20, 30, and 32), which are dependent on the generic Claim 8 with the understanding that upon the allowance of the linking claim (Claim 8), applicant will be entitled to consideration of claims 17, 18, 20, 30, and 32 which are written in dependent form. This election is made with traverse.

Amendments

The specific changes to the amended claims are shown on a separate page attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this page, the insertions are double underlined while the ~~deletions are struck through~~.

Please charge any fees, including any fees for extension of time, to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11/1/02

By: Mark R. Benedict

Mark R. Benedict
Registration No. 44,531
Attorney of Record
Customer No. 20,995
(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. **(Twice amended)** A transgenic non-human mammal comprising ~~the~~ an isolated or purified polynucleotide ~~of claim 1~~ encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease.
14. **(Twice amended)** A method of producing a transgenic animal, comprising:
- constructing a vector that carries ~~the~~ an isolated or purified polynucleotide of ~~claim 1~~ encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease;
 - introducing said vector into embryonic stem cells;
 - injecting said embryonic stem cells into blastocysts; and
 - placing said blastocysts into a pseudopregnant female animal.